Search Results 141-150 of 23212 for B cell lymphomas
Bone marrow transplant, CAR-T cell therapy, B-cell lymphoma, Waldenstrom macroglobulinemia, Non-Hodgkin lymphoma, Folli...cular lymphoma, Hodgkin lymphoma.
... B-cell lymphomas and leukemias into remission. However, leukemia and lymphoma tumors can change over time and become resistant to therapies, resulting in a ...
Most B-cell lymphomas are caused by changes in transcription factors and chromatin modifier genes. Transcription factors affect genetic information. Dr.
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer ...
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer ... B-cell lymphomas. Clinically, four weekly doses of rituximab have proven to ...
Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx Testing) into the routine work-up of diffuse large B-cell lymphoma ...
... Cells Predicts Survival Post-Autologous Stem Cell Transplantation in Lymphomas. ... cell therapy for large B-cell lymphoma: the Mayo Clinic experience. Leuk ...
Chronic lymphocytic leukemia/small lymphocytic lymphoma, monoclonal B-cell lymphocytosis, and B-cell prolymphocytic leukemia. In: Hematopathology. 3rd ed ...
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · Overview.
The purpose of this study is to determine how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.